New Large-Scale Meta-Analysis Demonstrates Strong Prognostic Performance of Myriad's Prolaris® Biopsy Test in Localized Prostate Cancer

Myriad Genetics, Inc. (NASDAQ: MYGN) announced new data from a large-scale meta-analysis of its Prolaris® Biopsy Test.

The study, published in Clinical Genitourinary Cancer, involved 14 studies and over 8,000 patients with localized prostate cancer.

Results demonstrate that the Prolaris Biopsy Test provides significant prognostic information beyond conventional clinical risk categories.

This evidence supports the use of Prolaris in risk stratification for localized prostate cancer, aiding in management discussions and shared decision-making.

The Prolaris test may help clinicians identify patients suitable for active surveillance versus those who might require treatment or treatment escalation.

The meta-analysis showed that the Prolaris combined clinical risk score (CCR) was significantly prognostic for distant metastasis and prostate cancer-specific mortality.